Sugi Predict

Sugi Predict / Compounds / SCHEMBL762264

SCHEMBL762264

SCHEMBL762264

Cc1nn(C)c(C)c1CN

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ LMNA P02545 2/20 0.37
▸ RAB9A P51151 5/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MPO P05164 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ ARG1 P05089 1/20 0.35
▸ NR2F2 P24468 2/20 0.34
▸ GALR3 O60755 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ TTR P02766 1/20 0.33
▸ NMT1 P30419 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5010811 0.98 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
Hydrochloric Acid SCHEMBL14696281 0.98 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL26050756 0.82 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL6760580 0.78 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL1751725 0.77 KDM4E (0.38) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL7993567 0.76 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL5898273 0.76 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL6744408 0.76 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
SCHEMBL5898267 0.76 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A
Hydrochloric Acid SCHEMBL16049975 0.76 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1KDM4ELMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 — — EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US claimed
EP-4050005-B1 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2024-12-25 — — EP disclosed
CN-113735916-B Method for converting terminal alkyne into amide and application of method in construction of gene coding library 康龙化成(宁波)科技发展有限公司 2023-11-14 — — CN disclosed
CN-115806550-A Bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2023-03-17 — — CN disclosed
CN-109641886-B Bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2022-11-18 — — CN disclosed
EP-4050005-A1 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2022-08-31 — — EP disclosed
CN-111285806-B Pyrazole compound and preparation method, application and pharmaceutical composition thereof 中国医学科学院药物研究所 2022-04-15 — — CN disclosed
EP-3380469-B1 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2022-03-16 — — EP disclosed
CN-113735916-A Method for converting terminal alkyne into amide and application of method in construction of gene coding library 康龙化成(宁波)科技发展有限公司 2021-12-03 — — CN disclosed
US-11028079-B2 Small molecule BET bromodomain inhibitors and uses thereof CONVERGENE, LLC (US) 2021-06-08 — — US disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
EP-1765817-A1 THIAZOLINONE UNSUBSTITUTED QUINOLINES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-28 — — EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US disclosed
WO-2006073366-A1 NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed
WO-2006002829-A1 THIAZOLINONE UNSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-01-12 — — WO disclosed
US-20060004045-A1 Thiazolinone unsubstituted quinolines CHEN LI 2006-01-05 — — US disclosed
US-20050182093-A1 Novel compounds GLAXOSMITHKLINE S.P.A. 2005-08-18 — — US disclosed
US-20050080258-A1 Pyridine and pyrimidine derivatives GENTEX CORPORATION 2005-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182093-A1 Novel compounds SLC10A1, AVPR2, REN SMN1; SMN2 1123/4885ALDH1A1 1675/4885KDM4E 3699/4885
US-11028079-B2 Small molecule BET bromodomain inhibitors and uses thereof BRDT, BRD4, BRD3 SMN1; SMN2 3432/4885ALDH1A1 4433/4885KDM4E 874/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL SMN1; SMN2 4705/4885ALDH1A1 1278/4885KDM4E 3446/4885
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors MMP13, MMP9, ADAMTS13 SMN1; SMN2 1621/4885ALDH1A1 601/4885KDM4E 1084/4885
US-20050080258-A1 Pyridine and pyrimidine derivatives ROR1, MAPK1, IRAK1 SMN1; SMN2 3752/4885ALDH1A1 682/4885KDM4E 1283/4885
US-20060004045-A1 Thiazolinone unsubstituted quinolines CDK1, CDK17, CDK14 SMN1; SMN2 2258/4885ALDH1A1 4173/4885KDM4E 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.